Cyclacel Pharma (CYCC) Submits Answers to Declaratory Judgement Complaint Filed by Celgene (CELG)

June 18, 2010 7:06 AM EDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation (Nasdaq: CELG). Cyclacel has filed counterclaims charging Celgene with infringement of each of four Cyclacel-owned patents and seeks damages for Celgene's infringement as well as injunctive relief. The four patents directly involve the use and administration of Celgene's ISTODAX® (romidepsin for injection) product.

The declaratory judgment complaint seeks to have the four Cyclacel patents, which claim the use of romidepsin for injection in T-cell lymphomas, declared invalid and not infringed by Celgene's products.

The four Cyclacel patents which are the subject of this action do not involve Cyclacel's clinical development candidates or its commercial products.

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment